Home LiteratureArticle Details
PMID: 18757774 Published · ppublish English Case Reports Journal Article

Colon perforation during antiangiogenic therapy for malignant glioma.

Neuro-oncology ·Vol. 11 ·No. 1 ·2009-02-00 ·Pages 92-5

Norden AD, Drappatz J, Ciampa AS, Doherty L, LaFrankie DC, Kesari S, Wen PY

Abstract

Antiangiogenic drugs have emerged as effective treatment options for patients with recurrent malignant gliomas (MGs). Though this class of drugs is generally well tolerated, rare life-threatening complications, including thromboembolism, hemorrhage, and gastrointestinal (GI) perforation, are reported. We describe six cases of GI perforation among 244 glioma patients (2.5%) during treatment with antiangiogenic agents in combination with chemotherapy and corticosteroids. Two patients succumbed to this complication, and the others recovered. Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangiogenic drug therapy who present with abdominal pain and other GI complaints.

MeSH Terms
Adult Aged Angiogenesis Inhibitors/therapeutic use Brain Neoplasms/blood supply,complications,drug therapy Glioma/blood supply,complications,drug therapy Humans Intestinal Perforation/chemically induced,drug therapy Middle Aged Neovascularization, Pathologic Treatment Outcome
Chemicals
Angiogenesis Inhibitors
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Norden Andrew D
Division of Neuro-Oncology, Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA. anorden@partners.org
Drappatz Jan
Ciampa Abigail Slate
Doherty Lisa
LaFrankie Debra Conrad
Kesari Santosh
Wen Patrick Y
References (14)
14 references, click to expand
  1. Use of corticosteroids in neuro-oncology.
    Anticancer Drugs. 1995 Feb;6(1):19-33 PMID: 7756680
  2. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?
    Gynecol Oncol. 2007 Apr;105(1):3-6 PMID: 17383545
  3. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
    N Engl J Med. 2004 Jun 3;350(23):2335-42 PMID: 15175435
  4. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
    Cancer Cell. 2007 Jan;11(1):83-95 PMID: 17222792
  5. Sigmoid diverticular perforation in neurosurgical patients receiving high-dose corticosteroids.
    Neurosurgery. 1993 Jul;33(1):40-3 PMID: 8355846
  6. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
    J Clin Oncol. 2005 Nov 1;23(31):8033-40 PMID: 16258101
  7. Management of bevacizumab-associated bowel perforation: a case series and review of the literature.
    Ann Oncol. 2008 Mar;19(3):577-82 PMID: 18024857
  8. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.
    Clin Cancer Res. 2007 Feb 15;13(4):1253-9 PMID: 17317837
  9. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.
    J Clin Oncol. 1999 Aug;17(8):2572-8 PMID: 10561324
  10. Perforation of the gastrointestinal tract in patients receiving steroids for neurologic disease.
    Neurology. 1988 Mar;38(3):348-52 PMID: 3258062
  11. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
    Curr Surg. 2006 Sep-Oct;63(5):334-7 PMID: 16971205
  12. Gastrointestinal perforation due to bevacizumab in colorectal cancer.
    Ann Surg Oncol. 2007 Jun;14(6):1860-9 PMID: 17356952
  13. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
    J Clin Oncol. 2006 Nov 20;24(33):5201-6 PMID: 17114652
  14. Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions.
    Ann Rheum Dis. 2004 May;63(5):588-90 PMID: 15082493
Article Info
Journal
Neuro-oncology
Abbr.
Neuro Oncol
ISSN
1522-8517
Published
2009-02-00
Epub
2008-00-29
Pages
92-5
Language
English
Region
England
NLM ID
100887420
PMCID
PMC2718964
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com